Phaseline

Companies › Corregene Biotechnology

Corregene Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KRAS-specific Autologous TCR-T cell injection (CRTKVA11-N04)
KRAS G12V-specific T-cell receptor engineered T-cell therapy
KRASPhase 1ColorectalNov 2028
CRTKVA11-03 TCR-T Cell Injection
KRAS G12V-specific autologous TCR-T cells
–Phase 1Advanced Solid TumorsDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06767046KRAS-specific Autologous TCR-T cell injection (CRTKVA11-N04)Phase 1ColorectalOncologyNov 2028
NCT07826585CRTKVA11-03 TCR-T Cell InjectionPhase 1Advanced Solid TumorsOncologyDec 2029

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.